Despite the variety of antibiotics currently available, bacterial infections remain a significant and growing medical problem. Many bacterial infections are serious and require hospitalization and treatment with injectable antibiotics.

Among the most common bacterial infections are those caused by Gram-positive bacteria, which include staphylococci, streptococci and enterococci. Gram-positive infections are often serious and life-threatening. The need for more effective antibiotics is particularly acute because many Gram-positive strains, particularly many staphylococci, have become resistant to currently available antibiotics. Of particular note are infections due to methicillin-resistant Staphylococcus aureus (commonly known as MRSA). Drug resistance is especially common in hospital-acquired infections.

Antibiotic Product Candidate — Telavancin for the Treatment of Nosocomial Pneumonia
In April 2009 the U.S. Food and Drug Administration accepted for filing a New Drug Application (NDA) for telavancin for the treatment of nosocomial pneumonia. The telavancin NDA is based on data from two large, multi-center, multinational, double-blind, randomized Phase 3 clinical studies, ATTAIN 1 and ATTAIN 2, in which 1,503 patients were enrolled and treated, 464 of whom were infected with MRSA.

Antibiotic Product Candidate — TD-1792
TD-1792 is an investigational heterodimer antibiotic that combines the antibacterial activities of a glycopeptide and a beta-lactam in one molecule. The goal of the TD-1792 clinical program is to develop a next-generation antibiotic for the treatment of serious infections caused by MRSA.